Teva Pharma's 2024 Shareholder Meeting: Growth & Innovation Focus

Ticker: TEVJF · Form: DEF 14A · Filed: Apr 16, 2024 · CIK: 818686

Teva Pharmaceutical Industries Ltd DEF 14A Filing Summary
FieldDetail
CompanyTeva Pharmaceutical Industries Ltd (TEVJF)
Form TypeDEF 14A
Filed DateApr 16, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$1.225 billion, $19,833 m, $21,212 million, $16.6 billion, $18.4 billion
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, annual-meeting, strategy, pharmaceuticals

Related Tickers: TEVA

TL;DR

Teva's 2024 shareholder meeting is here, focusing on innovation, generics, and pipeline progress. Expect growth.

AI Summary

Teva Pharmaceutical Industries Ltd. is holding its 2024 Annual Meeting of Shareholders, as detailed in this DEF 14A filing. Chairman of the Board, Dr. Sol J. Barer, expressed excitement about continued progress in 2024, focusing on innovative growth initiatives, high-value generics, and clinical milestones for pipeline assets. The company's mission is to provide access to quality medicines globally, driving its strategic focus.

Why It Matters

This filing outlines Teva's strategic direction and priorities for the upcoming year, impacting its ability to deliver on its mission of global medicine access and shareholder value.

Risk Assessment

Risk Level: medium — Proxy statements can indicate upcoming strategic shifts or shareholder votes that may carry financial implications.

Key Players & Entities

  • TEVA PHARMACEUTICAL INDUSTRIES LIMITED (company) — Registrant
  • Dr. Sol J. Barer (person) — Chairman of the Board of Directors
  • Richard Francis (person) — President and CEO

FAQ

What is the primary purpose of this DEF 14A filing?

This DEF 14A filing serves as the Proxy Statement for Teva Pharmaceutical Industries Ltd.'s 2024 Annual Meeting of Shareholders, detailing important information for shareholders to consider when voting.

Who is the Chairman of the Board of Directors at Teva?

Dr. Sol J. Barer is the Chairman of the Board of Directors at Teva Pharmaceutical Industries Ltd.

What are Teva's key focus areas for 2024 according to the Chairman?

The Chairman, Dr. Sol J. Barer, highlighted continued progress in innovative growth initiatives, execution on high-value, complex generics with new product launches, and achieving clinical milestones for late-stage pipeline assets.

What is Teva's stated mission?

Teva's mission is to advance scientific innovation to help improve health outcomes for millions of patients around the world and to ensure everyone, everywhere has access to quality medicines.

When did Teva's pivot to growth strategy begin?

The filing mentions that Teva's pivot to growth strategy began in May 2023.

Filing Stats: 4,501 words · 18 min read · ~15 pages · Grade level 14.4 · Accepted 2024-04-16 16:10:21

Key Financial Figures

  • $1.225 billion — rowth, with AUSTEDO revenues growing to $1.225 billion in 2023, and AJOVY now launched in most
  • $19,833 m — f December 31, 2023, our total debt was $19,833 million, compared to $21,212 million as o
  • $21,212 million — l debt was $19,833 million, compared to $21,212 million as of December 31, 2022. As of December
  • $16.6 billion — of December 31, 2023, our net debt was $16.6 billion compared to $18.4 billion as of Decembe
  • $18.4 billion — net debt was $16.6 billion compared to $18.4 billion as of December 31, 2022. In the past se
  • $17 billion — have reduced our net debt by more than $17 billion. 4 Teva Pharmaceutical Industries L
  • $2.49 billion — y 2045 - In March 2023, Teva issued $2.49 billion (equivalent) in aggregate principal amo

Filing Documents

Executive Compensation

Executive Compensation 39 HR and Compensation Committee Interlocks and Insider Participation 97 Proposal 2: Advisory Vote on Compensation of Named Executive Officers 98 Proposal 3: Advisory Vote on Frequency of Advisory Vote on Compensation of Named Executive Officers 99 Proposal 4: Appointment of Independent Registered Public Accounting Firm 100 Presentation of 2023 Financial Statements 102

Security Ownership

Security Ownership 103 Securities Authorized for Issuance Under Equity Compensation Plans 104 Related Party Transactions 105 Shareholder Proposals for the 2024 Annual Meeting and the 2025 Annual Meeting 107 Incorporation by Reference 108 Householding of Proxy Materials 108 Questions and Answers About the Annual Meeting 109 Appendix A 116 Teva Pharmaceutical Industries Ltd. 2024 Proxy Statement i Table of Contents Cautionary Note Regarding Forward-Looking Statements This proxy statement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as "should," "expect," "anticipate," "estimate," "target," "may," "project," "guidance," "intend," "plan," "believe" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Risks that could cause actual results to differ from those expressed or implied in such forward-looking statements are set forth in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the section captioned "Risk Factors," and other documents we may subsequently file with the Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. ii Teva Pharmaceutical Industries

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.